{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:09:25Z","timestamp":1793164165388,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40264-018-0642-6","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T07:40:22Z","timestamp":1519803622000},"page":"625-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-1889","authenticated-orcid":false,"given":"John F.","family":"Marcinak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin S.","family":"Munsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neila","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature01478","volume":"422","author":"Y Itoh","year":"2003","unstructured":"Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422:173\u20136.","journal-title":"Nature"},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.2337\/db08-0307","volume":"57","author":"S Edfalk","year":"2008","unstructured":"Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57:2280\u20137.","journal-title":"Diabetes"},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"11303","DOI":"10.1074\/jbc.M211495200","volume":"278","author":"CP Briscoe","year":"2003","unstructured":"Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278:11303\u201311.","journal-title":"J Biol Chem"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1124\/jpet.111.183772","volume":"339","author":"Y Tsujihata","year":"2011","unstructured":"Tsujihata Y, Ito R, Suzuki M, et al. TAK-875, an orally available G protein-coupled receptor 40\/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther. 2011;339:228\u201337.","journal-title":"J Pharmacol Exp Ther"},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1124\/jpet.111.187708","volume":"340","author":"H Yashiro","year":"2012","unstructured":"Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40\/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2012;340:483\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0091270011409230","volume":"52","author":"H Naik","year":"2012","unstructured":"Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 2012;52:1007\u201316.","journal-title":"J Clin Pharmacol"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/clpt.2012.43","volume":"92","author":"E Leifke","year":"2012","unstructured":"Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharm Ther. 2012;92:29\u201339.","journal-title":"Clin Pharm Ther"},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","volume":"379","author":"CF Burant","year":"2012","unstructured":"Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1403\u201311.","journal-title":"Lancet"},{"key":"642_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/dom.12467","volume":"17","author":"K Kaku","year":"2015","unstructured":"Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015;17:675\u201381.","journal-title":"Diabetes Obes Metab"},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/dom.12693","volume":"18","author":"K Kaku","year":"2016","unstructured":"Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes Obes Metab. 2016;18:925\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"642_CR11","first-page":"50","volume":"157","author":"FS Wolenski","year":"2017","unstructured":"Wolenski FS, Zhu AZX, Johnson M, et al. Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury. Toxicol Sci. 2017;157:50\u201361.","journal-title":"Toxicol Sci"},{"key":"642_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1463-1326.2011.01525.x","volume":"14","author":"T Araki","year":"2012","unstructured":"Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:271\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"642_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2337\/dc12-0872","volume":"36","author":"K Kaku","year":"2013","unstructured":"Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36:245\u201350.","journal-title":"Diabetes Care"},{"key":"642_CR14","unstructured":"US Food and Drug Administration. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. Drug Safety. 2009. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/..\/guidances\/UCM174090.pdf\n                    \n                  . Accessed 12 Apr 2017."},{"key":"642_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel\u2013Uclaf causality assessment method. Hepatology. 2010;51:2117\u201326.","journal-title":"Hepatology"},{"key":"642_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"642_CR17","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s40264-014-0184-5","volume":"37","author":"M Merz","year":"2014","unstructured":"Merz M, Lee KR, Kullak-Ublick GA, Brueckner A, Watkins PB. Methodology to assess clinical liver safety data. Drug Saf. 2014;37(Suppl 1):S33\u201345.","journal-title":"Drug Saf"},{"key":"642_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cld.2013.07.014","volume":"17","author":"A Regev","year":"2013","unstructured":"Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis. 2013;17:749\u201367.","journal-title":"Clin Liver Dis"},{"key":"642_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cpt.564","volume":"101","author":"M Mosedale","year":"2017","unstructured":"Mosedale M, Watkins PB. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101:469\u201380.","journal-title":"Clin Pharmacol Ther"},{"key":"642_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfx040","author":"MA Otieno","year":"2017","unstructured":"Otieno MA, Snoeys J, Lam W, et al. Fasiglifam (TAK 875): Mechanistic investigation and retrospective identification of hazards for drug induced liver injury. Toxicol Sci. 2017. \n                    https:\/\/doi.org\/10.1093\/toxsci\/kfx040\n                    \n                   (Epub 16 Feb 2017).","journal-title":"Toxicol Sci"}],"updated-by":[{"DOI":"10.1007\/s40264-018-0745-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-0642-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T23:30:53Z","timestamp":1551310253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-0642-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0642-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40264-018-0745-0","asserted-by":"object"}]},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]},"assertion":[{"value":"28 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article, the ALT and AST values in Fig.\u00a05a\u2013e were capped at 10\u00d7 ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig.\u00a05a\u2013e (Fig.\u00a01a\u2013e) and the correct Fig.\u00a05a\u20135e (Fig.\u00a02a\u2013e) are published.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"John F. Marcinak and Neila Smith are employed by Takeda Development Center Americas, Inc. (Deerfield, IL, USA). Melvin S. Munsaka is a former employee of Takeda Development Center Americas, Inc. Paul B. Watkins has served as a compensated consultant for Takeda regarding the liver safety of TAK-875 and other drugs. He received no compensation for the preparation of this article. Takashi Ohira is employed by Takeda Pharmaceutical Company Limited (Chuo-ku, Osaka, Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}